Pharma BD Deal Intelligence

Bristol-Myers Squibb Company / Repare Therapeutics Inc.

2020 · Licensing/Option · $3.1B · Complete

Announcement Sentiment

100

Strongly positive

Bristol-Myers Squibb and Repare Therapeutics entered a global research collaboration and license agreement to discover, develop and commercialize novel synthetic lethality precision oncology drug candidates. Repare received $50M cash + $15M equity upfront and is eligible for up to ~$3B in license, discovery, development, regulatory and sales milestones plus royalties.

Key facts

Announced May 26, 2020
Closed May 26, 2020
Deal value $3.1B
Deal type Licensing/Option
Therapeutic area Multiple oncology indications via DNA damage response targets
Indications Multiple oncology indications via DNA damage response targets
Key assets Synthetic lethality precision oncology programs (lead RP-3500/camonsertib)
Mechanism Synthetic lethality (DDR pathway inhibitors)

See the full interactive analysis, sources & comparables →

← Browse all deals · How we score deals